GRI Bio reports Phase 2a IPF biomarker and safety data
GRI Bio said Phase 2a translational biomarker and safety data for GRI-0621 showed a placebo-adjusted Week 12 FVC gain overall and on background antifibrotic therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.